Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
$995.00 – $2,995.00
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.
Figure 1 (Thumbnail). Enhancement of solubility for tanespimycin is shown in the representative images. Tanespimycin is insoluble in aqueous media at the specified concentration (2.5 mg/mL). Matched concentration of tanespimycin liposomes is shown.
Figure 2. DLS analysis of Tanespimycin Liposomes, Formulation XT28.1 (batch 65234). The average size and PDI of triplicate measurements are annotated on the representative snapshot from DLS data acquisition screen. The data are representative of a typical batch.
|Alias(es)||17-AAG; CP127374; NSC-330507; KOS 953|
|Signaling Pathway||Heat shock response (HSR) pathway|
|Hydration Solution||300 mM sucrose|
|External Solution||300 mM sucrose|
|Average Size||70-120 nm|
|2 °C to 8 °C (do not freeze), protect from light|
|Shelf Life*||At least 1 month|
*Product is too new for long-term stability data. This section will be updated regularly as new data becomes available.